Bio2 Technologies will present the poster at the Orthopaedic Research Society annual meeting on March 22, 2017, in San Diego.
Here are six key points:
1. Fort Collins-based Colorado State University researchers conducted the study.
2. Vitrium is composed of bioactive glass, creating properties similar to cortical bone.
3. The study found the device offered:
• An effective and safe resorption/bone formation profile
• Stimulation of new bone formation to increase fusion rates
• Sufficient strength to bear/share physiologic loads
4. All patients experienced a reduction in motion at 26 weeks, meaning a fusion took place for both the Vitrium and PEEK implants.
5. The Vitrium device demonstrated strength in excess of the adjoining vertebral bodies during axial compressive load to failure testing, while the PEEK fusion failed at the fusion site.
6. Researchers concluded Vitrium features “ideal characteristics” of an interbody fusion device.
More articles on devices:
LinkSpine hires Tom McLeer as VP of sales and marketing: 5 notes
FDA clears Stryker’s AVAflex Vertebral Balloon System: 5 highlights
Intellijoint receives FDA clearance for direct anterior approach device — 4 details
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
